| Literature DB >> 29167393 |
Chris Leptak1, Joseph P Menetski2, John A Wagner3, Jiri Aubrecht4, Linda Brady5, Martha Brumfield6, William W Chin7, Steve Hoffmann2, Gary Kelloff8, Gabriela Lavezzari9, Rajesh Ranganathan10, John-Michael Sauer6, Frank D Sistare11, Tanja Zabka12, David Wholley13.
Abstract
Biomarkers can facilitate all aspects of the drug development process. However, biomarker qualification-the use of a biomarker that is accepted by the U.S. Food and Drug Administration-needs a clear, predictable process. We describe a multistakeholder effort including government, industry, and academia that proposes a framework for defining the amount of evidence needed for biomarker qualification. This framework is intended for broad applications across multiple biomarker categories and uses.Mesh:
Substances:
Year: 2017 PMID: 29167393 DOI: 10.1126/scitranslmed.aal4599
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956